HU0201722D0 - - Google Patents

Info

Publication number
HU0201722D0
HU0201722D0 HU0201722A HUP0201722A HU0201722D0 HU 0201722 D0 HU0201722 D0 HU 0201722D0 HU 0201722 A HU0201722 A HU 0201722A HU P0201722 A HUP0201722 A HU P0201722A HU 0201722 D0 HU0201722 D0 HU 0201722D0
Authority
HU
Hungary
Application number
HU0201722A
Other languages
Hungarian (hu)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HU0201722D0 publication Critical patent/HU0201722D0/hu
Publication of HUP0201722A2 publication Critical patent/HUP0201722A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0201722A 2001-05-23 2002-05-22 Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére HUP0201722A2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29308801P 2001-05-23 2001-05-23

Publications (2)

Publication Number Publication Date
HU0201722D0 true HU0201722D0 (enExample) 2002-07-29
HUP0201722A2 HUP0201722A2 (hu) 2003-07-28

Family

ID=23127615

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0201722A HUP0201722A2 (hu) 2001-05-23 2002-05-22 Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére

Country Status (11)

Country Link
US (2) US20030130322A1 (enExample)
EP (1) EP1262196A3 (enExample)
JP (1) JP2002370975A (enExample)
KR (1) KR20020090153A (enExample)
CN (1) CN1386503A (enExample)
AU (1) AU4068602A (enExample)
CA (1) CA2386740A1 (enExample)
HU (1) HUP0201722A2 (enExample)
NZ (1) NZ519032A (enExample)
PL (1) PL354110A1 (enExample)
ZA (1) ZA200204019B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2350327C2 (ru) * 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
US8758443B2 (en) 2005-05-06 2014-06-24 Titan Spine, Llc Implants with integration surfaces having regular repeating surface patterns
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
TW200803901A (en) * 2005-11-28 2008-01-16 Orexigen Therapeutics Inc Methods of treating anxiety disorders
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
MX2009006672A (es) * 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
NZ588037A (en) 2008-02-28 2012-08-31 Univ Virginia Patent Found Serotonin transporter gene SLC6A4 and treatment of alcoholism
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
SI2801625T1 (en) 2010-07-02 2018-04-30 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug addiction
US20130096173A1 (en) 2011-09-09 2013-04-18 Bankole A. Johnson Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
CN114588467B (zh) * 2022-04-01 2022-11-29 广州蓝仕威克医疗科技有限公司 一种基于气体混合比例供气解决酒精中毒的方法及呼吸机
CN115671107B (zh) * 2022-12-29 2023-04-04 文韬创新药物研究（北京）有限责任公司 用于解酒的复方药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA923283B (en) * 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
DK0782445T3 (da) * 1994-09-19 2002-05-06 Bristol Myers Squibb Pharma Co Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
HUP0105488A3 (en) * 1999-02-23 2005-07-28 Pfizer Prod Inc Monoamine reuptake inhibitors for treatment of cns disorders and pharmaceutical compositions containing the compounds
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
WO2001027068A1 (en) * 1999-10-13 2001-04-19 Pfizer Products Inc. Biaryl ether derivatives useful as monoamine reuptake inhibitors

Also Published As

Publication number Publication date
ZA200204019B (en) 2003-11-21
CN1386503A (zh) 2002-12-25
JP2002370975A (ja) 2002-12-24
US20040162316A1 (en) 2004-08-19
HUP0201722A2 (hu) 2003-07-28
EP1262196A2 (en) 2002-12-04
NZ519032A (en) 2003-10-31
EP1262196A3 (en) 2002-12-18
AU4068602A (en) 2002-12-05
PL354110A1 (en) 2002-12-02
CA2386740A1 (en) 2002-11-23
US20030130322A1 (en) 2003-07-10
KR20020090153A (ko) 2002-11-30

Similar Documents

Publication Publication Date Title
BE2022C531I2 (enExample)
BE2022C547I2 (enExample)
BE2022C502I2 (enExample)
BE2017C059I2 (enExample)
BE2017C055I2 (enExample)
BE2017C051I2 (enExample)
BE2017C032I2 (enExample)
BE2016C051I2 (enExample)
BE2014C052I2 (enExample)
BE2014C036I2 (enExample)
BE2014C026I2 (enExample)
BE2007C047I2 (enExample)
AU2002307149A8 (enExample)
BE2011C034I2 (enExample)
JP2001237895A5 (enExample)
BE2014C006I2 (enExample)
BRPI0209186B1 (enExample)
BRPI0204884B1 (enExample)
CH1379220H1 (enExample)
BE2016C043I2 (enExample)
BE2014C008I2 (enExample)
BE2016C021I2 (enExample)
BRPI0101486B8 (enExample)
BE2012C051I2 (enExample)
BRMU8103221U (enExample)

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees